"Pulmonary Endothelial Cell Barrier Enhancement by Novel FTY720 Analogs: Methoxy-FTY720, Fluoro-FTY720, and β-Glucuronide-FTY720".

[1]  H. Stark,et al.  Novel oxazolo-oxazole derivatives of FTY720 reduce endothelial cell permeability, immune cell chemotaxis and symptoms of experimental autoimmune encephalomyelitis in mice , 2014, Neuropharmacology.

[2]  E. Letsiou,et al.  FTY720 (S)-Phosphonate Preserves Sphingosine 1-Phosphate Receptor 1 Expression and Exhibits Superior Barrier Protection to FTY720 in Acute Lung Injury , 2014, Critical care medicine.

[3]  D. Hafler,et al.  Fingolimod for multiple sclerosis. , 2012, The New England journal of medicine.

[4]  S. Pyne,et al.  (R)-FTY720 methyl ether is a specific sphingosine kinase 2 inhibitor: Effect on sphingosine kinase 2 expression in HEK 293 cells and actin rearrangement and survival of MCF-7 breast cancer cells. , 2011, Cellular signalling.

[5]  N. Suttorp,et al.  The Sphingosine-1 Phosphate receptor agonist FTY720 dose dependently affected endothelial integrity in vitro and aggravated ventilator-induced lung injury in mice. , 2011, Pulmonary pharmacology & therapeutics.

[6]  T. Hla,et al.  Engagement of S1P₁-degradative mechanisms leads to vascular leak in mice. , 2011, The Journal of clinical investigation.

[7]  S. Dudek,et al.  FTY720-induced human pulmonary endothelial barrier enhancement is mediated by c-Abl , 2010, European Respiratory Journal.

[8]  J. Chun,et al.  Prolonged exposure to sphingosine 1-phosphate receptor-1 agonists exacerbates vascular leak, fibrosis, and mortality after lung injury. , 2010, American journal of respiratory cell and molecular biology.

[9]  S. Dudek,et al.  Synthetic Analogs of FTY720 [2-Amino-2-(2-[4-octylphenyl]ethyl)-1,3-propanediol] Differentially Regulate Pulmonary Vascular Permeability in Vivo and in Vitro , 2009, Journal of Pharmacology and Experimental Therapeutics.

[10]  Steven J Brown,et al.  Sphingosine 1-phosphate receptor signaling. , 2009, Annual review of biochemistry.

[11]  R. Bittman,et al.  Chiral vinylphosphonate and phosphonate analogues of the immunosuppressive agent FTY720. , 2009, The Journal of organic chemistry.

[12]  S. Dudek,et al.  Regulation of vascular permeability by sphingosine 1-phosphate. , 2009, Microvascular research.

[13]  H. Nagasawa,et al.  TX-2152: a conformationally rigid and electron-rich diyne analogue of FTY720 with in vivo antiangiogenic activity. , 2008, Bioorganic & medicinal chemistry.

[14]  T. Macdonald,et al.  Asymmetric synthesis of conformationally constrained fingolimod analogues--discovery of an orally active sphingosine 1-phosphate receptor type-1 agonist and receptor type-3 antagonist. , 2007, Journal of medicinal chemistry.

[15]  Brandon A Brown,et al.  Fingolimod: A Novel Immunosuppressant for Multiple Sclerosis , 2007, The Annals of pharmacotherapy.

[16]  S. Dudek,et al.  Pulmonary endothelial cell barrier enhancement by FTY720 does not require the S1P1 receptor. , 2007, Cellular signalling.

[17]  R. Proia,et al.  Essential Requirement for Sphingosine Kinase 2 in a Sphingolipid Apoptosis Pathway Activated by FTY720 Analogues* , 2007, Journal of Biological Chemistry.

[18]  G. Bernard,et al.  Acute lung injury and the acute respiratory distress syndrome: a clinical review , 2007, The Lancet.

[19]  G. Cirino,et al.  Sphingosine-1-phosphate/sphingosine kinase pathway is involved in mouse airway hyperresponsiveness. , 2007, American journal of respiratory cell and molecular biology.

[20]  G. Charron,et al.  Constrained azacyclic analogues of the immunomodulatory agent FTY720 as molecular probes for sphingosine 1-phosphate receptors. , 2007, Bioorganic & medicinal chemistry letters.

[21]  Ludwig Kappos,et al.  Oral fingolimod (FTY720) for relapsing multiple sclerosis. , 2006, The New England journal of medicine.

[22]  Gabor Tigyi,et al.  The FASEB Journal express article 10.1096/fj.05-4810fje. Published online November 30, 2005. ©2005 FASEB , 2022 .

[23]  Diane P. Martin,et al.  Incidence and outcomes of acute lung injury. , 2005, The New England journal of medicine.

[24]  Michael D. Davis,et al.  Synthesis, stability, and implications of phosphothioate agonists of sphingosine-1-phosphate receptors. , 2005, Bioorganic & medicinal chemistry letters.

[25]  S. Dudek,et al.  Regulation of sphingosine 1‐phosphate‐induced endothelial cytoskeletal rearrangement and barrier enhancement by S1P1 receptor, PI3 kinase, Tiam1/Rac1, and α‐actinin , 2005, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[26]  T. Meade,et al.  A Gadolinium Chelate for Detection of β-Glucuronidase: A Self-Immolative Approach , 2005 .

[27]  Michael D. Davis,et al.  Synthesis of 4(5)-phenylimidazole-based analogues of sphingosine-1-phosphate and FTY720: discovery of potent S1P1 receptor agonists. , 2005, Bioorganic & medicinal chemistry letters.

[28]  J. Chun,et al.  S1P3 receptor-induced reorganization of epithelial tight junctions compromises lung barrier integrity and is potentiated by TNF. , 2005, Proceedings of the National Academy of Sciences of the United States of America.

[29]  B. Simon,et al.  Sphingosine 1-phosphate reduces vascular leak in murine and canine models of acute lung injury. , 2004, American journal of respiratory and critical care medicine.

[30]  G. Chrebet,et al.  Selecting against S1P3 enhances the acute cardiovascular tolerability of 3-(N-benzyl)aminopropylphosphonic acid S1P receptor agonists. , 2004, Bioorganic & medicinal chemistry letters.

[31]  G. Chrebet,et al.  Potent S1P receptor agonists replicate the pharmacologic actions of the novel immune modulator FTY720. , 2004, Bioorganic & medicinal chemistry letters.

[32]  S. Dudek,et al.  Pulmonary Endothelial Cell Barrier Enhancement by Sphingosine 1-Phosphate , 2004, Journal of Biological Chemistry.

[33]  H. Rabb,et al.  Protective effects of sphingosine 1-phosphate in murine endotoxin-induced inflammatory lung injury. , 2004, American journal of respiratory and critical care medicine.

[34]  R. Proia,et al.  Immune Cell Regulation and Cardiovascular Effects of Sphingosine 1-Phosphate Receptor Agonists in Rodents Are Mediated via Distinct Receptor Subtypes , 2004, Journal of Pharmacology and Experimental Therapeutics.

[35]  K. Claffey,et al.  Phosphorylation and Action of the Immunomodulator FTY720 Inhibits Vascular Endothelial Cell Growth Factor-induced Vascular Permeability* , 2003, Journal of Biological Chemistry.

[36]  J. Garcia,et al.  Role of Ca2+ in diperoxovanadate-induced cytoskeletal remodeling and endothelial cell barrier function. , 2003, American journal of physiology. Lung cellular and molecular physiology.

[37]  S. Spiegel,et al.  Sphingosine‐1‐phosphate stimulates contraction of human airway smooth muscle cells , 2003, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[38]  J. Garcia,et al.  S1P induces FA remodeling in human pulmonary endothelial cells: role of Rac, GIT1, FAK, and paxillin. , 2003, Journal of applied physiology.

[39]  T. Ohmori,et al.  Enhancement of sphingosine 1-phosphate-induced migration of vascular endothelial cells and smooth muscle cells by an EDG-5 antagonist. , 2002, Biochemical and biophysical research communications.

[40]  N. Mochizuki,et al.  Development of novel EDG3 antagonists using a 3D database search and their structure-activity relationships. , 2002, Journal of medicinal chemistry.

[41]  H. Rosen,et al.  Alteration of Lymphocyte Trafficking by Sphingosine-1-Phosphate Receptor Agonists , 2002, Science.

[42]  S. Dudek,et al.  Cytoskeletal regulation of pulmonary vascular permeability. , 2001, Journal of applied physiology.

[43]  A. Verin,et al.  Sphingosine 1-phosphate promotes endothelial cell barrier integrity by Edg-dependent cytoskeletal rearrangement. , 2001, The Journal of clinical investigation.

[44]  J. Smit,et al.  Enantioselective synthesis of a novel trans double bond ceramide analogue via catalytic asymmetric dihydroxylation of an enyne. The role of the trans double bond of ceramide in the fusion of semliki forest virus with target membranes , 1999 .

[45]  Bruce L. Murphy,et al.  An Efficient Synthesis of Florfenicol. , 1991 .

[46]  R. Bizios,et al.  Thrombin‐induced increase in albumin permeability across the endothelium , 1986, Journal of cellular physiology.

[47]  J. Garland.  The New England Journal of Medicine. , 1961, Canadian Medical Association journal.

[48]  E. E. Parker,et al.  Amino Acids. IV. Amino Acids Related to Serine , 1945 .